Workflow
QX035N
icon
Search documents
荃信生物完成TruMed基金约1亿港元新H股配售,自免领域实力获专业投资者认可
IPO早知道· 2025-08-26 04:04
配售聚焦于筹措资金和引入长线投资人两个方面。 本文为IPO早知道原创 作者|罗宾 微信公众号|ipozaozhidao 据 IPO 早 知 道 消 息 , 8 月 25 日 , 荃 信 生 物 ( 2509.HK ) 宣 布 , 公 司 已 完 成 向 TruMed Health Innovation Fund LP(下称"TruMed")配售500万股股份, 配售价为每股 20.0港元,募集资金 总额约为1亿港元。 TruMed是一家专注于生物医药投资的专业投资机构 ,曾作为基石投资者深度参与科伦博泰、映恩 生物及维立志博等港股 IPO项目,具有很强的行业影响力 ,被誉为香港医疗健康投资领域的风向 标。 荃信生物专注于自身免疫及过敏性疾病生物疗法,管线覆盖皮肤、呼吸、消化、风湿四大治疗领域, 其中一个产品已获批上市,多个产品处于临床后期阶段。根据弗若斯特沙利文报告,全球自身免疫性 疾病及过敏性疾病药物市场预计将持续快速增长,到 2030年合计将达到2710亿美元规模。中国作 为新兴市场,存在大量未满足的临床需求,潜藏巨大发展空间。 近年来,公司先后与华东医药( 000963.SZ)、健康元(600380.S ...
荃信生物-B早盘涨超6% 上半年收入同比增超近3.6倍 公司配股筹资近1亿港元
Zhi Tong Cai Jing· 2025-08-18 03:24
Group 1 - The core viewpoint of the article highlights that Zai Lab Limited (荃信生物-B) experienced a significant increase in its stock price, rising over 6% following the release of its interim financial results [1] - The company reported a revenue of RMB 206 million, representing a year-on-year increase of 359.69% [1] - The net loss for the period was RMB 30.93 million, which is a reduction of 83.11% compared to the previous year [1] Group 2 - The revenue primarily consisted of income from licensing agreements, including an upfront payment related to the overseas licensing of QX030N and a non-cash consideration for approximately 24.88% equity in Caldera Therapeutics, totaling RMB 181 million [1] - Additional revenue was generated from CDMO services and R&D services for projects QX004N and QX008N, amounting to approximately RMB 22 million [1] - The company announced a placement of 5 million new shares to TruMed Health Innovation Fund LP at a price of HKD 20 per share, raising approximately HKD 99 million, with about 60% allocated for repaying existing interest-bearing bank loans [1][1]
港股异动 | 荃信生物-B(02509)早盘涨超6% 上半年收入同比增超近3.6倍 公司配股筹资近1亿港元
智通财经网· 2025-08-18 03:17
Core Viewpoint - Zai Lab Limited (荃信生物-B) reported significant revenue growth and reduced losses in its interim results, indicating strong operational performance and strategic developments [1] Financial Performance - The company achieved revenue of RMB 206 million, representing a year-on-year increase of 359.69% [1] - The net loss for the period was RMB 30.93 million, a decrease of 83.11% compared to the previous year [1] Revenue Breakdown - Revenue primarily included income from licensing agreements, which accounted for RMB 181 million, including upfront payments related to QX030N and a non-cash consideration for approximately 24.88% equity in Caldera Therapeutics [1] - Additional revenue of approximately RMB 22 million was generated from CDMO services and R&D services for projects QX004N and QX008N [1] Capital Raising - The company announced a placement of 5 million new shares to TruMed Health Innovation Fund LP at a price of HKD 20 per share, raising approximately HKD 99 million [1] - Approximately 60% of the net proceeds will be used to repay existing interest-bearing bank loans, 30% for the development of new pipelines including QX027N, QX031N, and QX035N, and 10% for working capital and other corporate purposes [1]
荃信生物-B(02509)拟折让约10.95%配售500万股配售股份 净筹约9900万港元
智通财经网· 2025-08-18 00:00
待配售事项完成后,并假设所有配售股份成功配售,预期配售事项所得款项净额(经扣除配售事项费用 及配售事项的其他相关成本及开支)将约为9900万港元。公司拟将配售事项所得款项净额(经扣除发行开 支)分配如下:配售所得款项净额约60%,用于偿还现有计息银行借款。于2025年上半年,公司产生额 外银行借款以支付其研发开支,导致其资产负债率上升。以所得款项净额偿还该等借款将加强公司的财 务状况,降低其有息负债比率,减少其财务开支,最终减轻整体财务风险;配售事项所得款项净额约 30%,用于公司的新管线研发,包括QX027N、QX031N及QX035N;及配售事项所得款项净额约10%,用 作营运资金及其他企业用途。 智通财经APP讯,荃信生物-B(02509)发布公告,于2025年8月18日(交易时段前),公司与配售代理订立 配售协议,据此,配售代理有条件同意作为公司的配售代理向一名承配人(其本身及其最终实益拥有人 (如适用)将为独立第三方)按配售价每股配售股份20.0港元配售500万股配售股份。 假设已发行股份数目于本公告日期至配售交割日期期间并无变动,配售事项下的配售股份占(i)本公告日 期已发行股份数目约2.25%; ...